KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Link
http://www.nature.com/articles/1210558.pdf
Reference29 articles.
1. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B et al. (2005). Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11: 4182–4190.
2. Bauer S, Hartmann JT, de Wit M, Lang H, Grabellus F, Antoch G et al. (2005a). Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117: 316–325.
3. Bauer S, Hubert C, Heinrich MC, Cohen PS, Bertagnolli MM, Demetri GD et al. (2005b). KIT hyperactivation in imatinib-resistant GIST: implications for salvage therapies. Proc Am Soc Clin Oncol 23: a9034.
4. Bauer S, Yu LK, Demetri GD, Fletcher JA . (2006). Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66: 9153–9161.
5. Cammenga J, Horn S, Bergholz U, Sommer G, Besmer P, Fiedler W et al. (2005). Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood 106: 3958–3961.
Cited by 223 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance;Cancers;2024-09-07
2. ONCOLINER: A new solution for monitoring, improving, and harmonizing somatic variant calling across genomic oncology centers;Cell Genomics;2024-09
3. Brefeldin A and M-COPA block the export of RTKs from the endoplasmic reticulum via simultaneous inactivation of ARF1, ARF4, and ARF5;Journal of Biological Chemistry;2024-06
4. KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST;Cell Communication and Signaling;2024-02-27
5. Hallmarks and novel insights for gastrointestinal stromal tumors: A bibliometric analysis;European Journal of Surgical Oncology;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3